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Safety and efficacy of routine postoperative ibuprofen for pain and
disability related to ectopic bone formation after hip replacement
surgery (HIPAID): randomised controlled trial
Marlene Fransen, Craig Anderson, Jan Douglas, Stephen MacMahon, Bruce Neal, Robyn Norton, Mark Woodward,
Ian D Cameron, Ross Crawford, Sing Kai Lo, Garnet Tregonning, Margaret Windolf, for the HIPAID Collaborative
Group
Abstract
Objectives To determine the benefits and risks of a
non-steroidal anti-inflammatory drug (NSAID) as prophylaxis
for ectopic bone formation in patients undergoing total hip
replacement (or revision) surgery.
Design Double blind randomised placebo controlled clinical
trial, stratified by treatment site and surgery (primary or
revision).
Setting 20 orthopaedic surgery centres in Australia and New
Zealand.
Participants 902 patients undergoing elective primary or
revision total hip replacement surgery.
Intervention 14 days’ treatment with ibuprofen (1200 mg daily)
or matching placebo started within 24 hours of surgery.
Main outcome measures Changes in self reported hip pain
and physical function 6 to 12 months after surgery (Western
Ontario and McMaster University Arthritis index).
Results There were no significant differences between the
groups for improvements in hip pain (mean difference − 0.1,
95% confidence interval − 0.4 to 0.2, P = 0.6) or physical
function ( − 0.1, − 0.4 to 0.2, P = 0.5), despite a decreased risk of
ectopic bone formation (relative risk 0.69, 0.56 to 0.83)
associated with ibuprofen. There was a significantly increased
risk of major bleeding complications in the ibuprofen group
during the admission period (2.09, 1.00 to 4.39).
Conclusions These data do not support the use of routine
prophylaxis with NSAIDs in patients undergoing total hip
replacement surgery.
Trial registration NCT00145730.
Introduction
Chronic symptomatic osteoarthritis of the hip is common in
those aged ≥ 50 and total hip replacement is a well established
and highly effective treatment.1 While surgery reduces pain and
improves physical function in most people, residual symptoms
are common.2–4 One determinant of the risk of long term pain
and disability after hip replacement is ectopic bone—abnormal
bone that forms postoperatively in the soft tissues around the
operated hip.5 Some ectopic bone occurs in more than one third
of all patients who undergo hip replacement.6 Both the risk of
occurrence and the severity, as judged from radiographic meas-
urements, can be greatly reduced by a short course of postopera-
tive non-steroidal anti-inflammatory drugs (NSAIDs).7
Routine prophylaxis with a short course of postoperative
NSAIDs has been advocated for all patients undergoing total hip
arthroplasty8 9 because it is not possible preoperatively to identify
patients at risk of developing ectopic bone. All recent
randomised clinical trials are uniformly characterised by the lack
of a placebo group. Before the widespread introduction of such
a preventive strategy, more evidence is required about the
balance of benefits and risks, particularly in light of recent
concerns about the safety of some NSAIDs.10 Specifically we
need to determine whether improvements in radiographic
abnormalities produced with NSAIDs result in worthwhile ben-
efits for long term pain and physical function.7 We also need to
determine whether there are any safety issues.
We established the effects of a routine short course of
postoperative ibuprofen11 12 on pain and physical function 6 to
12 months after total hip replacement surgery.We also evaluated
the effect of treatment on other measures of physical function,
radiographic ectopic bone formation, and bleeding complica-
tions.
Methods
We carried out this double blind, randomised, placebo controlled
trial in patients undergoing elective total hip replacement
surgery at 20 hospitals in Australia and New Zealand between
February 2002 and May 2004. All patients provided written
informed consent, and an independent safety and monitoring
committee reviewed the data during recruitment. Details of the
study methods and implementation strategy have been
published elsewhere.13
Participants—Patients identified within 24 hours of completed
elective total hip replacement surgery (primary or revision) were
eligible for inclusion, irrespective of age, reason for surgery, or
procedure performed. Patients were ineligible if there was, in the
opinion of the responsible physician, a definite indication for
treatment with an NSAID during the 14 day study treatment
period (for example, patients in whom no other analgesic agent
was deemed suitable) or a definite contraindication for treatment
with an NSAID (for example, previous serious adverse reaction
to an NSAID, previous major gastrointestinal bleed, serious renal
impairment, or known bleeding disorder). In addition, patients
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who had taken an NSAID (other than low dose aspirin) in the 48
hours before the operation were not eligible nor were patients
with a postoperative spinal catheter in situ unless the catheter
had been removed at least two hours before randomisation.14
Randomisation—Randomisation was performed centrally by
using a computer based system accessible 24 hours a day via a
toll-free telephone call within 24 hours after surgery. On confir-
mation of eligibility, researchers used a minimisation algorithm15
to provide a unique randomisation code corresponding to a
treatment pack held at the centre. We used a minimisation pro-
gram to stratify treatment by study centre and type of surgery
performed (primary or revision). Treatment allocation was
blinded and concealed from patients and study staff until the
database was locked.
Treatment and control—Participants were randomised to
receive 14 days of treatment with either ibuprofen (2×200 mg
tablets three times daily) or matching placebo tablets. All study
tablets were packaged in identical blister packs. Treatment was
scheduled to start within 24 hours after surgery and patients
could not take other NSAIDs (with the exception of low dose
aspirin) during the study period. The protocol required no other
changes to usual preoperative or postoperative care.
Data collection and follow-up—Demographic variables and
baseline clinical data were obtained during the usual
pre-admission clinic visit, typically one to two weeks before
surgery. Information about the anaesthetic and surgical
techniques, postoperative care, and early indicators of bleeding
complications was collected during hospital admission. All other
outcomes were recorded at a routine follow-up visit scheduled,
depending on the operating centre, for between 6 months and
12 months after surgery. Serious adverse events in hospital were
documented as they occurred and were specifically inquired
about during the 14 day monitoring telephone call and at the
follow-up visit. All assessments were standardised and per-
formed blind to randomised treatment allocation.
Outcomes—Our primary study outcomes were the changes
from baseline to follow-up in self reported hip pain and physical
function measured by the Western Ontario and McMaster
Universities arthritis index (WOMAC) questionnaire (Likert ver-
sion).16 We standardised scores to a range of 0-10, with 0 indicat-
ing no hip pain or no difficulty with daily activities and 10
indicating severe hip pain or severe difficulty with daily activities.
Secondary outcomes were general health status (summary scale
scores on physical and mental components17) of the medical out-
comes study short form 36 (SF-36)18); patients’ global assessment
of effectiveness of treatment (hip status compared with before
surgery; hip status today) with five response levels; frequency of
use of analgesia for hip pain during the past week; ability to get
“about the house” and ability to get “out of the house” with five
response levels ranging from “not at all” to “no difficulty”; time
spent participating in physical activity during the past week;
objective measures of physical performance (hip flexion,19 time
to walk 50 feet (about 15 metres), and timed “up and go”20);
radiographic evidence of ectopic bone formation according to
the Brooker classification21; and major bleeding complications
during hospital admission (bleeding from the wound for more
than three days, evacuation of a wound haematoma, haematem-
esis, melaena, other serious bleeding event). Red cell transfusions
(or re-infusions), suction drainage volumes, and postoperative
haemoglobin concentrations (measured ≥ 48 hours after
surgery) were also recorded.
Analysis—We planned to recruit 1000 patients to provide 90%
power (= 0.05) to detect a difference of ≥ 10% between the
randomised groups for each of the two primary outcomes.13 The
actual sample size of 902 achieved at the end of the recruitment
period provided 87% power to detect these effects. We used t
tests to evaluate changes in the primary outcomes of pain and
physical function (WOMAC) and health related quality of life
(SF-36) and to compare differences in other continuous
outcome measures at follow-up. In each case we calculated the
estimated difference between randomised groups, the 95% con-
fidence interval of the difference, and the corresponding P value.
We compared categorical outcomes for the proportions of
patients with events with 2 tests to obtain a P value and
calculated the relative risk and 95% confidence intervals. For
ordinal outcomes we evaluated the effects of randomised
treatment by fitting a proportional odds model and calculating
the odds ratio (and 95% confidence intervals) of an improved
outcome with ibuprofen.15 In each case we tested the assumption
of proportionality and found it was not violated. All analyses
were done according to the principle of intention to treat. We
carried forward baseline assessments when follow-up data were
missing.
Results
We were able to randomise only 902 patients because of slow
recruitment and funding limitations (452 to ibuprofen and 450
to placebo, figure). Baseline data were missing for four (0.4%)
and primary outcome data were missing for 27 (6%) allocated to
ibuprofen and 22 (5%) allocated to placebo (figure). Of those
who completed the primary outcomes assessment, 823 (96%)
assessments were conducted during an outpatient clinic visit and
the remainder by telephone. The median (range) period of
follow-up was 7.6 months (5-18 months) and 7.9 months (5-20
months) for the ibuprofen and placebo groups, respectively.
Only 16 (2%) outcomes assessments (6 and 10 participants
respectively) occurred 14 or more months after surgery.
Standard anteroposterior radiographs, scheduled to be taken 6
to12 months after surgery, were obtained for 798 (88%) partici-
pants. There was no significant difference between the two allo-
cation groups in follow-up rates for any of the outcome
measures.
Baseline characteristics
The mean age of participants was 66, and 54% were men. Most
had a diagnosis of osteoarthritis and were undergoing a primary
hip replacement. The groups were well balanced regarding
demographics, clinical history, surgical technique, and anaesthe-
sia (table 1).
Adherence to randomised treatment
In total 875 (97%) patients started the randomised treatment,
and 188 (21%) stopped prematurely (106 (24%) in the ibuprofen
group and 82 (19%) in the placebo group, P = 0.06, figure).
Treatment was stopped, usually on medical advice and mainly
because of suspected side effects or intolerance (11% v 8%,
P = 0.13) or other unspecified medical reasons (8% v 7%,
P = 0.34).
Effects of randomised treatment
Pain and physical function—There was no significant differences
between the groups for improvements in hip pain (mean differ-
ence − 0.1, 95% confidence interval − 0.4 to 0.2, P = 0.59) or
physical function ( − 0.1, − 0.4 to 0.2, P = 0.48) 6 to 12 months
after surgery (table 2).
Secondary clinical outcome measures—There were no significant
differences between the groups on the secondary clinical
outcomes of general health status (table 2), global assessments
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(table 3), participation in physical activity, or objective measures
of physical performance (table 4). Furthermore, the odds of hav-
ing a better outcome in terms of global assessment of
effectiveness of treatment (hip status today, mobility “out of the
house”) or use of analgesia for hip pain were not significantly
increased among patients allocated to ibuprofen (table 3).
Bleeding complications during admission—There was a signifi-
cantly increased risk of major bleeding complications among
those in the ibuprofen group (risk ratio 2.09, 1.00 to 4.39,
P = 0.046) (table 5). There were no significant differences
between groups in the proportion of patients requiring red cell
transfusion (ibuprofen 37% v placebo 34%, P = 0.35), suction
drainage volumes (415 ml v 424 ml, P = 0.71), or postoperative
haemoglobin concentrations measured ≥ 48 hours after surgery
(105 g/l v 105 g/l, P = 0.80). The latter result was materially
altered when we excluded transfused (or re-infused) patients
from the analyses (102 g/l v 100 g/l, P = 0.26).
Serious adverse events during follow-up—Eight participants died.
All deaths occurred between 6 days and 180 days after the end of
the study treatment (median 78 days) (table 5). The difference in
the numbers of serious adverse events between the allocation
groups was not significant.
Ectopic bone formation—There was a highly significant
decrease in the risk of developing ectopic bone of any grade
(0.69, 0.57 to 0.83) and in the risk of developing severe ectopic
bone (Brooker grade 3 or 4) (0.44, 0.22 to 0.88) among patients
in the ibuprofen group (table 6). The odds of developing a more
severe grade of ectopic bone with ibuprofen was 0.55 (0.41 to
0.73). Patients with Brooker grade 3 and 4 had higher pain and
disability scores than those with less severe grades of ectopic
bone formation, though this trend was not significant.
Discussion
Ibuprofen routinely administered after total hip replacement
surgery does not result in better long term clinical outcomes,
despite significantly decreasing the risk of ectopic bone
formation. Postoperative ibuprofen also increases the risk of
serious bleeding complications.
We carried out this study because observational studies had
reported adverse effects of ectopic bone on clinical outcomes5
and earlier trials provided clear evidence that NSAIDs decreased
the occurrence of radiographic ectopic bone.7 We observed the
anticipated beneficial effect of ibuprofen on radiographic
outcomes but found no corresponding improvement in clinical
outcomes. The most plausible explanation for this finding is that
minor or moderate ectopic bone has little effect on clinical out-
Randomised (n=902)
Al
lo
ca
tio
n
Allocated to ibuprofen (n=452):
  Received allocated treatment (n=440)
  Did not receive allocated treatment (n=12):
    Medical reasons (n=4)
    Withdrew consent (n=2)
    Other reasons (n=6)
Allocated to placebo (n=450):
  Received allocated treatment (n=435)
  Did not receive allocated treatment (n=15):
    Medical reasons (n=5)
    Withdrew consent (n=2)
    Other reasons (n=8)
Fo
llo
w
-u
p
Lost to follow-up (WOMAC) (n=27):
  Died (n=4)
  Refused/too ill (n=5)
  Lost contact or unknown (n=18)
Discontinued ibuprofen (n=106):
  Drug side effects/intolerance (n=51)
  Other medical reasons (n=38)
  Withdrew consent (n=15)
  Other reasons (n=2)
Lost to follow-up (WOMAC) (n=22):
  Died (n=4)
  Refused/too ill (n=1)
  Lost contact or unknown (n=17)
Discontinued ibuprofen (n=82):
  Drug side effects/intolerance (n=37)
  Other medical reasons (n=30)
  Withdrew consent (n=12)
  Other reasons (n=3)
An
al
ys
is
Analysed (n=449):
  Excluded, no baseline data (n=3)
Analysed (n=449):
  Excluded, no baseline data (n=1)
Details of flow of participants through study
Table 1 Baseline characteristics and features of surgery in patients
undergoing hip replacement according to postoperative treatment. Figures
are numbers (percentages) of patients unless stated otherwise
Ibuprofen (n=449) Placebo (n=449)
Mean (SD) age (years) 66 (12) 67 (11)
Men 245 (54) 244 (54)
Diagnosis*:
Osteoarthritis 407 (90) 424 (94)
Inflammatory arthritis 11 (2) 4 (1)
Other 53 (12) 35 (8)
Charnley grading:
Unilateral hip 313 (70) 304 (68)
Bilateral hip 116 (26) 125 (28)
Multiple joint disease 20 (4) 20 (5)
Revision surgery 37 (8) 39 (9)
Duration >3 hours 50 (11) 55 (12)
Anaesthesia*:
General 257 (57) 255 (57)
Spinal 279 (62) 291 (65)
Epidural 38 (8) 43 (10)
Approach:
Anterior/anterolateral 129 (29) 137 (31)
Posterior/posterolateral 272 (60) 264 (59)
Other 50 (11) 47 (11)
Cemented components:
Acetabular 128 (28) 122 (27)
Femoral 266 (59) 275 (62)
Trochanteric osteotomy 58 (13) 55 (12)
Bone grafting 42 (9) 52 (12)
Anticoagulant regimen*:
Standard heparin 33 (7) 43 (10)
Low molecular weight heparin 237 (53) 241 (54)
Aspirin/antiplatelet 193 (43) 194 (43)
*Some patients had multiple diagnoses or more than one anaesthesia or anticoagulant
regimen.
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comes after hip arthroplasty. This explanation is supported by
the WOMAC pain and function subscales reported in table 6.
While severe ectopic bone (Brooker grades 3 and 4) can impair
outcome, this forms in only a small proportion of patients.
Hence, although a much larger trial might detect some beneficial
effect of ibuprofen on clinical outcomes, any such clinical benefit
would be small in absolute terms and probably inconsequential
in the context of the large improvement in clinical outcomes
achieved with joint replacement surgery itself.
The study treatment was generally well tolerated, with no sig-
nificant difference in rates of discontinuation between groups.
There was a borderline significant increase in major bleeds
among patients in the ibuprofen group, which might reflect the
antiplatelet effects of cyclo-oxygenase I inhibition.22 While there
was no clear effect of study treatment on other measures of
bleeding in the postoperative period, an increase in risk of
bleeding is consistent with the established effects of other
NSAIDs.23
Our results provide no evidence of clinical benefit 6 to 12
months postoperatively and raise concerns about the safety of
ibuprofen for the prevention of ectopic bone formation after hip
arthroplasty. There is no particular reason to believe that other
conventional NSAIDs would have produced materially different
results.23 24 These findings, therefore, suggest that recommenda-
tions promoting routine prophylaxis with a short course of post-
operative NSAIDs for all patients undergoing hip arthroplasty
are not justified.While some patients at high risk of ectopic bone
formation (such as those with a history of it) may derive clinical
benefits from prophylaxis with NSAIDs that outweigh any risks,
randomised trials are required to substantiate this. Our results
provide further evidence that guidelines for routine clinical care
in surgery, as in other specialties, must be based on clinically
important outcomes rather than surrogates such as radiographic
ectopic bone formation.25 Without such evidence, the wide-
spread use of routine prophylaxis with NSAIDs on the basis of
radiographic changes may well have resulted in net harm rather
than benefit.
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Table 2 Mean (SD) score for pain, physical function, and general health status before surgery (baseline) and at follow-up (6 to 12 months after surgery) in
patients undergoing hip replacement according to postoperative treatment with change and difference in change with 95% confidence intervals
Ibuprofen (n=449) Placebo (n=449)
Difference in change, P value
Baseline Follow-up Change Baseline Follow-up Change
Pain (0-10) 5.6 (1.9) 1.4 (2.0) 4.3 (4.1 to 4.5) 5.6 (1.9) 1.2 (1.8) 4.3 (4.1 to 4.5) −0.1 (−0.4 to 0.2), 0.6
Function (0-10) 6.0 (1.9) 1.9 (2.0) 4.1 (4.0 to 4.2) 6.0 (1.8) 1.8 (1.9) 4.2 (4.1 to 4.3) −0.1 (−0.4 to 0.2), 0.5
SF-36 (PCS) 30.8 (8.5) 45.2 (10.8) 14.4 (13.3 to 15.5) 31.5 (8.4) 45.6 (10.2) 14.1 (13.0 to 15.2) 0.4 (−1.2 to 1.9), 0.6
SF-36 (MCS) 46.2 (12.3) 53.9 (10.2) 7.7 (6.6 to 8.8) 46.3 (12.8) 54.6 (10.6) 8.4 (7.2 to 9.6) −0.7 (−2.3 to 0.9), 0.4
PCS=physical component summary scale score; MCS= mental component summary scale score.
Table 3 Numbers (percentages) of patients with global assessments 6 to 12
months after hip replacement according to postoperative treatment
Global assessments
Ibuprofen
(n=424)
Placebo
(n=424)
Odds ratio* (95%
CI)
Hip status today: excellent/very good 347 (82) 332 (78) 1.1 (0.9 to 1.5)
At least daily analgesics for hip pain 112 (26) 103 (24) 1.1 (0.8 to 1.4)
No problems walking “out of the house” 341 (80) 342 (81) 1.0 (0.7 to 1.4)
*Estimated constant per category changed, therefore not explicitly related to numbers (%) in
2nd and 3rd columns.
Table 4 Mean (SD) measures of physical activity and physical performance,
6 to 12 months after hip replacement according to postoperative treatment
Ibuprofen Placebo
Mean difference (95%
CI)
Physical activity (minutes/week)
No of patients with data 419 423 —
Walk outdoors >10 minutes 243 (290) 215 (276) 27.4 (−10.3 to 65.0)
Vigorous activity 143 (245) 125 (231) 16.6 (−14.8 to 50.3)
Vigorous exercise 41 (118) 34 (101) 6.8 (−8.2 to 21.9)
Moderate exercise 68 (157) 71 (141) −3.5 (−23.9 to 16.9)
Physical performance measures
No of patients with data 387 393 —
Hip flexion (degrees) 92.7 (18.4) 93.9 (17.4) −1.2 (−3.7 to 1.3)
Up and go (seconds) 9.9 (7.6) 9.7 (7.4) 0.2 (−0.6 to 1.0)
Time to walk 50 feet* (seconds) 14.2 (7.5) 14.5 (7.7) −0.3 (−1.4 to 0.8)
*About 15 metres.
Table 5 Adverse events during admission and follow-up after hip
replacement according to postoperative treatment
Ibuprofen Placebo
Patients with bleeding events (admission period)*
No (%) of patients with bleeding event 21 (5) 10 (2)
Bleeding from wound >3 days 11 8
Evacuation wound haematoma 3 2
Haematemesis 1 2
Melaena 4 1
Other bleeding event† 4 1
Serious adverse events (in 6 to 12 month follow-up)
No (%) of patients with serious adverse event 67 (15) 63 (14)
Death 4 4
Life threatening event 5 2
Permanent/substantial disability 7 8
Admission to hospital/prolonged admission 20 11
Medically important 31 38
*Some patients with more than one bleeding event
†Haemorrhage (2), haematuria, bleeding haemorrhoids.
Table 6 Ectopic bone formation and associated clinical outcomes (WOMAC
pain and function), 6 to 12 months after hip replacement surgery according
to postoperative treatment. Figures are numbers (percentages) of patients
with mean (SD) pain and function
Brooker grade
Ibuprofen
(n=391)
Placebo
(n=407)
Pain (0-10)
(n=798)
Function (0-10)
(n=798)
0 (none) 274 (70) 230 (57) 0.97 (1.47) 1.56 (1.57)
1 (mild) 78 (20) 108 (27) 0.99 (1.49) 1.43 (1.57)
2 (moderate) 28 (7) 43 (11) 0.97 (1.57) 1.87 (1.79)
3 (severe) 9 (2) 22 (5)
1.25 (1.85) 2.23 (1.95)
4 (bony ankylosis) 2 (0.5) 4 (1)
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What is already known on this topic
Ectopic bone, or abnormal bone that forms in local soft
tissues, is common after hip replacement surgery
A short course of postoperative NSAIDs greatly reduces the
risk of this abnormal radiographic outcome
As it is not possible to identify patients at risk, routine
prophylaxis has been recommended
What this study adds
Despite a significantly reduced rate of ectopic bone
formation among patients who took NSAIDs
postoperatively, there were no significant clinical benefits 6
to 12 months after surgery
Postoperative NSAIDs are also associated with an increased
risk of bleeding events among these patients, and routine
prophylaxis is not recommended
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